GGrantIndex
← Leaderboards

Brahm H. Segal

Roswell Park Cancer Institute Corp

$5,088,454
Attributed
$8,057,661
Total exposure
3
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $821.8K · FY200925
$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,057,661 · 3

By mechanism

R01$8,057,661 · 3

Top collaborators

Most similar at Roswell Park Cancer Institute Corp

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorInflammatoryNeutrophilMalignant NeoplasmsPathway InteractionsSignal TransductionAscitesEpithelial Ovarian CancerTumor MicroenvironmentTherapeutic TargetTumor ProgressionNeutrophil InfiltrationMouse ModelMalignant Neoplasm Of OvaryResponseFoundationsImmunotherapyInfectionMicrobialHost DefenseInflammationMitochondriaBloodApoptosis

Grant awards (15)

Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$642,760
R01 · FY2025 · CA
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$618,854
R01 · FY2024 · CA
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$645,738
R01 · FY2023 · CA
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$693,903
R01 · FY2022 · CA
Novel immunological biomarkers ovarian cancer prognosis$613,871
R01 · FY2019 · CA · contact PI
A CRISPR-based platform for testing neutrophil responses in the ovarian cancer microenvironment$207,918
R01 · FY2019 · CA · contact PI
Novel immunological biomarkers ovarian cancer prognosis$632,858
R01 · FY2018 · CA · contact PI
Novel immunological biomarkers ovarian cancer prognosis$646,389
R01 · FY2017 · CA · contact PI
Novel immunological biomarkers ovarian cancer prognosis$646,389
R01 · FY2016 · CA · contact PI
Novel immunological biomarkers ovarian cancer prognosis$589,735
R01 · FY2015 · CA · contact PI
Role of NADPH Oxidase in Regulating Inflammation$410,597
R01 · FY2013 · AI · contact PI
Role of NADPH Oxidase in Regulating Inflammation$431,525
R01 · FY2012 · AI · contact PI
Role of NADPH Oxidase in Regulating Inflammation$426,399
R01 · FY2011 · AI · contact PI
Role of NADPH Oxidase in Regulating Inflammation$425,678
R01 · FY2010 · AI · contact PI
Role of NADPH Oxidase in Regulating Inflammation$425,047
R01 · FY2009 · AI · contact PI